BioSpace News Archive

Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 shares of the Company’s c

Fitch upgrades the company’s long-term issuer default rating to BB-/Stable Company’s strong operating performance, portfolio management and strong competitive position cited as reasons for the upgrade [22-May-2020] RADNOR, Pa. , May 22, 2020 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR) (“Avantor” or the “Company”), a leading global provider of mission critical

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported the exercise of approximately 2.87 million previously issued Series P and Series Q warrants resulting in gross proceeds to the Company of approximately $3.53 million . The warrants

Castlight Health, Inc. (NYSE: CSLT) today announced the launch of Working WellTM, an end-to-end solution that helps employers of any size manage safe workforce re-entry in the rapidly shifting landscape of the COVID-19 pandemic.

Patisiran Continues to Demonstrate Reversal of Neuropathy Progression, Improvement in Quality of Life, and Consistent Safety Profile with Additional 24 Months of Treatment in Global Open-Label Extension (OLE) Study Interim Data Presented on Patisiran Treatment in Patients with Disease Progression After an Orthotopic Liver Transplant CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeut

CANTEL MEDICAL CORP. (NYSE:CMD) (“Cantel” or the “Company”) today announced the sale of $28 million in aggregate principal amount of its 3.25% convertible senior notes due 2025 in respect of the Company’s previously announced private offering of the notes to persons reasonably believed to be qualified institutional buyers pursua

Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid ® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The product may have up to 115.0% of the labeled amount of Liothyronine (T3). Risk Stateme

Livanta LLC was honored with a Spotlight Award from the Centers for Medicare & Medicaid Services (CMS) for The Livanta Compass e-newsletter. The weekly publication was recognized as an effective communication vehicle for reaching rural communities to build awareness of Livanta’s activities as a Medicare Beneficiary and Family Centered Care Quality Improvement Organization (BFCC-QIO). The inaugural Spotlight Awards were presented

INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, announced today that it will effect a 1-for-20 reverse stock split, previously approved by the Company’s Boa

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eagle is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only fo